![conference banner](/images/conference-banner.jpeg)
Abstract
Glitazones were introduced into clinical use to offer type II diabetic patients an alternative to oral hypoglycaemic agents. Unlike traditional agents based on β-pancreatic overstimulation, glitazones raise peripheral insulin sensitivity allowing the patient to efficiently use his own insulin. Although glitazones are only approved for the treatment of diabetes, their beneficial effects extend to every symptom of the so-called metabolic syndrome: they protect against atherosclerosis, inhibit blood coagulation, decrease hypertension and improve vascular endothelial function. Moreover, glitazones counteract activation of macrophages and brain microglia, attenuate the expression of pro-inflammatory genes, and inhibit various signalling events involved in inflammation. In addition, glitazones are able to induce cell differentiation and apoptosis in several cancer cells, suggesting possible use of these drugs for the treatment of gliomas and other tumors. The molecular basis of such a vast array of glitazone actions is necessarily complex. Glitazone effects were originally attributed to activation of peroxisome proliferator activated receptor-γ (PPARγ). However, several properties of glitazones are unrelated to PPARγ. We review here the emerging actions of glitazones focusing on their antihypertensive and anti-tumoral effects, PPARγ-dependent and – independent, and also emphasizing the contribution of mitochondria and reactive oxygen and nitrogen species to these actions.
Keywords: endothelial cell, Prostaglandins, Antitumor, proinflammatory, Reactive Oxygen Species
Current Drug Therapy
Title: Potential Benefits of Glitazones for Cancer and Vascular Disease
Volume: 3 Issue: 2
Author(s): Jose M. Perez-Ortiz, Silvia Llorens, Juan Llopis, Pedro A. Tranque and Eduardo Nava
Affiliation:
Keywords: endothelial cell, Prostaglandins, Antitumor, proinflammatory, Reactive Oxygen Species
Abstract: Glitazones were introduced into clinical use to offer type II diabetic patients an alternative to oral hypoglycaemic agents. Unlike traditional agents based on β-pancreatic overstimulation, glitazones raise peripheral insulin sensitivity allowing the patient to efficiently use his own insulin. Although glitazones are only approved for the treatment of diabetes, their beneficial effects extend to every symptom of the so-called metabolic syndrome: they protect against atherosclerosis, inhibit blood coagulation, decrease hypertension and improve vascular endothelial function. Moreover, glitazones counteract activation of macrophages and brain microglia, attenuate the expression of pro-inflammatory genes, and inhibit various signalling events involved in inflammation. In addition, glitazones are able to induce cell differentiation and apoptosis in several cancer cells, suggesting possible use of these drugs for the treatment of gliomas and other tumors. The molecular basis of such a vast array of glitazone actions is necessarily complex. Glitazone effects were originally attributed to activation of peroxisome proliferator activated receptor-γ (PPARγ). However, several properties of glitazones are unrelated to PPARγ. We review here the emerging actions of glitazones focusing on their antihypertensive and anti-tumoral effects, PPARγ-dependent and – independent, and also emphasizing the contribution of mitochondria and reactive oxygen and nitrogen species to these actions.
Export Options
About this article
Cite this article as:
Perez-Ortiz M. Jose, Llorens Silvia, Llopis Juan, Tranque A. Pedro and Nava Eduardo, Potential Benefits of Glitazones for Cancer and Vascular Disease, Current Drug Therapy 2008; 3 (2) . https://dx.doi.org/10.2174/157488508784221271
DOI https://dx.doi.org/10.2174/157488508784221271 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Renal Artery Stenosis: Current Perspectives on Imaging and Endovascular Management
Current Hypertension Reviews Percutaneous Coronary Intervention in the Elderly: Are Drug-coated Balloons the Future?
Current Cardiology Reviews A Review of Statistical and Machine Learning Techniques for Microvascular Complications in Type 2 Diabetes
Current Diabetes Reviews Determination of Interchangeability of Different Brands of Diclofenac Sodium Sustained Release Tablets in Healthy Subjects Using Pharmacokinetic End Points
Letters in Drug Design & Discovery Aldosteronism in Heart Failure: A Proinflammatory / Fibrogenic Cardiac Phenotype. Search for Biomarkers and Potential Drug Targets
Current Drug Targets Tetrahydrobiopterin Regulation of eNOS Redox Function
Current Pharmaceutical Design Effectiveness of a Standardized and Specific Follow-Up in Memory Centers in Patients with Alzheimer’s Disease
Current Alzheimer Research Use of Non-steroidal Anti-inflammatory Drugs in Pregnancy: Impact on the Fetus and Newborn
Current Drug Metabolism Recent Developments in Thrombin-Activatable Fibrinolysis Inhibitor Research
Mini-Reviews in Medicinal Chemistry Triphenylethylene-Coumarin Hybrid TCH-5c Suppresses Tumorigenic Progression in Breast Cancer Mainly Through the Inhibition of Angiogenesis
Anti-Cancer Agents in Medicinal Chemistry Bioreactors Design, Types, Influencing Factors and Potential Application in Dentistry. A Literature Review
Current Stem Cell Research & Therapy Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Inflammatory Molecular Mediators and Pathways Involved in Vascular Aging and Stroke: A Comprehensive Review
Current Medicinal Chemistry Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research The Role of Angiotensin in Obesity and Metabolic Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry Pulmonary Hypertension: Clinical Presentation, Diagnosis, Treatment,and Dana Point World Symposium Highlights
Current Respiratory Medicine Reviews Alzheimers and Dementia in the Oldest-Old: A Century of Challenges
Current Alzheimer Research Administration of Autologous Mesenchymal Cells for the Treatment of Arthritis
Current Stem Cell Research & Therapy Current Treatment of Relapsed Ovarian Carcinoma
Current Cancer Therapy Reviews